Correction to: Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis

被引：0

作者：

Sue Ping Thang

Mei Sim Lung

Grace Kong

Michael S. Hofman

Jason Callahan

Michael Michael

Rodney J. Hicks

机构：

[1] Centre for Cancer Imaging,Department of Nuclear Medicine and PET

[2] Peter MacCallum Cancer Centre,undefined

[3] Division of Cancer Medicine,undefined

[4] Neuroendocrine Tumour Unit,undefined

[5] Peter MacCallum Cancer Centre,undefined

[6] Singapore General Hospital,undefined

来源：

European Journal of Nuclear Medicine and Molecular Imaging | 2018年 / 45卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

On page 4 of the original version of this article, the text “Eight (29%) of the patients had significant FDG-avid disease (i.e. with intensity above liver parenchyma) prior to treatment” needs to be corrected.

引用

页码：323 / 323

共 48 条

[41] Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force
Prasad, Vikas
Koumarianou, Anna
Denecke, Timm
Sundin, Anders
Deroose, Christophe M.
Pavel, Marianne
Christ, Emanuel
Lamarca, Angela
Caplin, Martyn
Castano, Justo P.
Dromain, Clarisse
Falconi, Massimo
Grozinsky-Glasberg, Simona
Hofland, Johannes
Knigge, Ulrich Peter
Kos-Kudla, Beata
Krishna, Balkundi A.
Reed, Nicholas Simon
Scarpa, Aldo
Srirajaskanthan, Rajaventhan
Toumpanakis, Christos
Kjaer, Andreas
Hicks, Rodney J.
Ambrosini, Valentina
JOURNAL OF NEUROENDOCRINOLOGY, 2025, 37 (02)
[42] Single-institution experience with 18F-DOPA and 68Ga-DOTA-TOC as a PET imaging tracer for peptide receptor radionuclide therapy in well-differentiated neuroendocrine neoplasms
Veenstra, E.
Noordzij, W.
JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 199 - 199
[43] Peptide receptor radiopeptide therapy (PRRT) using the 225Actinium-and 225Actinium/177Lutetiumlabelled (TANDEM) somatostatin-receptor (SSTR) antagonist DOTA-LM3 in patients with neuroendocrine neoplasms (NEN): A retrospective study concerning safety and survival
Perrone, E.
Mishra, A.
Eismant, A.
Ghai, K.
Greifenstein, L.
Baum, R. P.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S125 - S125
[44] Long-term adverse events and survival of patients with neuroendocrine neoplasms (NEN) receiving peptide receptor radioligand therapy (PRRT) using 225Ac-and 225Ac-/177Lu-labeled (TANDEM) antagonist DOTA-LM3: A retrospective analysis
Perrone, Elisabetta
Mishra, Aditi
Eismant, Aleksandr
Ghai, Kriti
Greifenstein, Lukas
Baum, Richard P.
JOURNAL OF NUCLEAR MEDICINE, 2024, 65
[45] Intravenous and intra-arterial peptide receptor radionuclide therapy (PRRT) using Y-90-DOTA-Tyr3-OCTREOTATE (Y-90 DOTA-TATE) in patients with metastatic neuroendocrine tumors
Baum, RP
Söldner, J
Schmücking, M
Niesen, A
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S238 - S238
[46] Safety and efficacy of 213Bi-[DOTA0,Tyr3]octreotide (Bi-DOTA-TOC) in peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors in a pre-clinical model.
Norenberg, JP
Krenning, BJ
Konings, IR
De Jong, M
Atcher, RW
Kusewitt, DF
Kvols, LK
CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3732S - 3732S
[47] PFS and OS After Salvage Peptide Receptor Radionuclide Therapy (PRRT) With 177-Lu[Dota0,Tyr3]octreotate in Patients With GastroEnteroPancreatic or Bronchial NeuroEndocrine Tumours (GEP-NETs): The Rotterdam Cohort
van der Zwan, Wouter
Brabander, Tessa
Kam, Boen
Teunissen, Jaap
Krenning, Eric
Kwekkeboom, Dik
de Herder, Wouter
PANCREAS, 2018, 47 (03) : 357 - 357
[48] Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3 A Somatostatin Receptor Antagonist
Zhang, Jingjing
Kulkarni, Harshad R.
Singh, Aviral
Baum, Richard P.
CLINICAL NUCLEAR MEDICINE, 2020, 45 (03) : E165 - E168

← 1 2 3 4 5 →